{
    "nct_id": "NCT05792722",
    "official_title": "A Prospective, Randomized Trial Comparing Prostate Capsule-sparing and Nerve-sparing Radical Cystectomy in Patients With Bladder Cancer",
    "inclusion_criteria": "* Subjects with pathologically confirmed bladder cancer scheduled for radical cystectomy\n* Variant histologies of bladder cancer permitted\n* Neoadjuvant therapy permitted\n* Age > 18 years old\n* Ability to understand and willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients that are not candidates for cystectomy\n* Moderate to severe erectile dysfunction with SHIM score <17\n* Bladder cancer with bladder neck or prostatic involvement, including cancer in the prostatic urethra\n* Prior pelvic radiation\n* Confirmed prostate cancer:\n* Patients with abnormal Digital rectal exam (DRE), PSA >3 or Prostate Imaging Reporting & Data System (PIRADS) 4 lesions on prostate Multiparametric MRI (mpMRI) will undergo prostate biopsy to rule out prostate cancer\n* Increased genetic risk of prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines:\n* ≥1 first-, second-, or third-degree relative with: breast cancer at age ≤50 y, colorectal or endometrial cancer at age ≤50 y, male breast cancer at any age, ovarian cancer at any age, exocrine pancreatic cancer at any age, metastatic, regional, very-high-risk, high-risk prostate cancer at any age\n* ≥1 first-degree relative (father or brother) with: prostate cancer at age ≤60 y\n* ≥2 first-, second-, or third-degree relatives with: breast cancer at any age, prostate cancer at any age\n* ≥3 first- or second-degree relatives with: Lynch syndrome-related cancers, especially if diagnosed\n* Patients with Lynch syndrome",
    "miscellaneous_criteria": ""
}